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INTRODUCTION
Tuberculosis (TB) is a infectious disease caused by Mycobacterium 
tuberculosis  (MTB). Among various forms of tuberculosis, pulmonary 
tuberculosis is the most common with the involvement of lung 
macrophages containing a large number of bacilli. Effective chemotherapy 
of pulmonary tuberculosis has been proposed through pulmonary delivery 
of biodegradable microparticles incorporating antituberculosis drugs. We 
have demonstrated administration of dry powder inhalations (DPI) of 
microparticles containing anti-TB drugs to various laboratory animals, 
which can target drugs to macrophages while decreasing bioavailability to 
blood and blood-perfused organs. The biodistribution of antituberculosis 
drugs has always remained a challenge and is responsible for the 
requirement of daily administration of these drugs during TB 
chemotherapy. In the present study, a DPI comprising anti-tuberculosis 
drugs incorporated in biodegradable microparticles was delivered by nose-
only inhalation to mice. Poly L-lactic acid (PLA) microparticles 
incorporating a high payload of rifabutin and isoniazid were fabricated by 
spray drying to develop a sustained-release, macrophage-targeting 
delivery system containing the two drugs. Microparticles of desired high 
encapsulation efficiency and sustained release characteristics were 
produced having a diameter range of 1-10µm. Time-dependent 
biodistribution of rifabutin and isoniazid after single inhalation dose of 
drug loaded microparticles was established using a validated HPLC 
bioanalytical method. We studied the pharmacokinetics of the two drugs in 
target cells (alveolar macrophages) and lung tissue, as well as in the liver 
and kidneys, where their toxicity is most commonly manifested. Equivalent 
doses of free rifabutin and isoniazid were administered intravenously for 
comparison. 
OBJECTIVES
• To prepare and characterize poly (D,L-lactic acid) microparticles 
containing rifabutin and isoniazid
• To evaluate the time kinetics of biodistribution of the two drugs i.e. 
Rifabutin and Isoniazid in the lungs, liver and kidneys of mice
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This study shows that drugs incorporated in microparticles 
generate high concentration and maintain therapeutic levels in 
lungs. Based on favorable biodistribution kinetics, these 
microparticles have the potential to reduce dosing frequency 
and toxicity of anti-TB drugs 
 Spray drying yielded rifabutin and isoniazid incorporated in 
PLA microparticles having median particle diameter between 
1-10µm with narrow size distribution which is appropriate for 
endocytosis by alveolar macrophages 
 In the present study, inhalation of microparticles resulted in 
effective accumulation of the incorporated drugs in the lungs. 
At the same time, intravenous administration of equivalent 
amounts did not result in selective accumulation in targeted 
organ i.e. lungs. 
 All the organs examined showed detectable levels of drug. 
Levels of isoniazid and rifabutin in lungs (target organ) were 
much higher than those in the liver and kidney of mice in case 
of inhalation as compared to intravenous administration. 
Inhalation of microparticles resulted in targeting of both the 
drugs to the lungs. The relative bioavailability of both drugs 
incorporated in microparticles was significantly higher 
compared with free drugs. 
High and prolonged drug concentrations and increased AUC 
values (~9-fold and ~6 fold increase of rifabutin and isoniazid 
in case of lungs) with respect to free drugs were observed. 
Significant decrease in drug concentration was found in the 
liver and kidneys. These results confirm that inhalable 
microparticles are suitable for targeting and providing 
sustained release of anti-TB drugs to lungs. 
Targeted delivery of RFB to the lungs led to substantial 
reduction in first-pass metabolism of RFB. The findings 
suggest that polymeric microparticles prepared by spray 
drying process offer promises for treating pulmonary TB with 
reduced doses, lower dosing frequency and alleviated toxicity. 
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DIFFERENTIAL SCANNING CALORIMETRY
DSC thermograms showing melting temperature of PLA matrix(curve-2) containing Isoniazid( 
curve-1), Rifabutin(curve-6) and conbination of  both (curve-5). Isoniazid(curve-3) and rifabutin 
(curve-4)
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